Saturday 17 October 2026 Export INCR’s income statement to Excel — free account

InterCure Ltd.

INCR Healthcare Drug Manufacturers Specialty & Generic

InterCure Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $78.5 million, up 18.4% from fiscal 2024.

4.66 0.01 +0.22%

Follow INCR

Alert me

Market cap: $55.1M
P/E: 8.8×
Fwd P/E: 0.0×
Dividend yield: —
F-score: 5/9
Altman Z: 0.14
Beneish M: −2.77
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 15.77%

Capital & Financial Ratios $m

Market Cap 55.10

Revenue 120.19

Net Income 1.22

Free Cash Flow (0.81)

Net Debt 17.49

Current Ratio 1.85

Debt/Equity 0.27

P/E ratio 8.80

Fwd P/E 0.00

P/S ratio 0.33

P/B ratio 0.33

Past 5Y EPS Growth —

This Y EPS Growth 97.14%

Next Y EPS Growth 1,550.00%

Next Y revenue growth 274.17%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 9.40%

10-year low 10-year high

P/S against its own 10 years 7.32%

10-year low 10-year high

P/B against its own 10 years 7.52%

10-year low 10-year high

EV/Sales against its own 10 years 14.49%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2022	2023	2024	2025
Cash	74	30	22	14
Receivables	40	55	50	46
Inventory	38	29	34	31
Other	—	—	—	—
	151	114	106	92

	2022	2023	2024	2025
Payables	38	21	21	20
ST’ Debt	0	—	—	3
Other	3	1	10	1
	93	61	61	62

Compound Annual Growth %

	10y	5y	3y
Sales	—	31.11%	(13.13%)
Cash Flow	—	15.01%	(31.58%)
Earnings	—	0.00%	0.00%
Book Value	—	6.13%	(9.51%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	78
’24	—	—	—	—	66
’23	31	—	—	—	97
’22	29	29	29	33	120
’21	10	14	20	26	70
’20	—	3	7	8	20

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	3	—	—	5
’24	—	—	—	—	(18)
’23	(15)	—	—	—	(15)
’22	1	0	1	13	15
’21	2	3	3	2	8
’20	—	(1)	2	3	2

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	3	—	—	4
’24	—	—	—	—	(19)
’23	(15)	—	—	—	(15)
’22	(1)	(1)	0	11	9
’21	2	2	2	2	3
’20	—	(1)	2	3	2

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	(0.95)
’24	—	—	—	—	(2.00)
’23	0.00	—	—	—	(1.85)
’22	0.55	0.50	0.25	0.25	1.50
’21	0.03	0.20	(0.05)	(0.02)	0.15
’20	—	(0.01)	0.02	0.12	(0.46)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	4.75	1.50	5.75	16.35	4.95	5.85	3.40	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	21.75	11.00	49.95	41.00	20.00	18.60	8.95
People
People	Employees	—	—	—	—	—	350	370	270	320	285
	Revenue/emp, $m	—	—	—	0.00	0.00	0.20	0.32	0.36	0.21	0.28
Income, $m
Income, $m	Revenue	—	—	—	3	20	70	120	97	66	78
	Gross margin, %	—	0.00	0.00	13.07	45.58	40.28	38.60	29.54	12.32	12.27
	EBT	0	(2)	(3)	(2)	(12)	6	13	(17)	(24)	(13)
	EBT margin, %	0.00	0.00	0.00	(69.75)	(58.90)	8.28	10.91	(17.22)	(35.60)	(16.32)
	Net income	0	0	(3)	(2)	(12)	2	13	(17)	(20)	(11)
	Depreciation	—	0	0	0	1	2	3	4	4	5
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.11	0.80	9.10	13.20	10.60	7.23	7.30
	Earnings	0.01	(0.09)	(0.19)	(0.07)	(0.46)	0.20	1.50	(1.85)	(2.00)	(0.95)
	Cash flow	(0.02)	(0.02)	(0.02)	(0.14)	0.10	1.01	1.68	(1.60)	(1.97)	0.46
	Capex	0.00	0.00	0.00	0.00	0.00	(0.56)	(0.65)	(0.08)	(0.14)	(0.10)
	Free cash flow	(0.02)	(0.02)	(0.02)	(0.14)	0.10	0.44	1.04	(1.68)	(2.11)	0.36
	Book value	0.50	0.35	0.29	3.18	3.37	18.46	17.13	13.62	11.71	10.71
	Shares, m	13	17	18	23	25	8	9	9	9	11
Valuation, ×
Valuation, ×	P/E	—	—	—	50.92	50.92	205.98	11.09	12.31	15.01	8.59
	P/S	—	—	—	0.00	0.00	21.03	1.34	0.46	0.57	0.32
	P/B	—	—	—	2.73	2.05	10.12	1.04	0.39	0.55	0.32
	EV/Sales	—	—	—	0.00	0.00	20.52	1.04	0.62	0.85	0.65
	EV/FCF	—	—	—	0.00	0.00	140.88	13.24	(17.76)	(24.50)	(96.54)
Cash, $m
Cash, $m	Operating cash flow	0	0	0	(3)	2	8	15	(15)	(18)	5
	Capex	0	—	0	(8)	(6)	(4)	(6)	(1)	(1)	(1)
	Free cash flow	0	0	0	(3)	2	3	9	(15)	(19)	4
Balance, $m
Balance, $m	Working capital	0	0	(3)	6	15	44	58	52	45	30
	Total debt	1	1	3	5	2	11	37	28	37	26
	Net debt	0	0	2	(3)	(10)	(57)	(37)	(2)	15	12
	Shareholders’ equity	6	6	5	74	86	142	155	124	107	115
Returns, %
Returns, %	ROA	0.98	(43.41)	(40.62)	(3.74)	(12.66)	0.92	5.36	(6.74)	(8.73)	(5.10)
	ROIC	0.00	0.00	0.00	0.00	0.00	6.37	7.94	(5.79)	(9.23)	(3.90)
	ROE	1.13	(25.66)	(60.96)	(4.30)	(14.54)	1.28	8.98	(12.04)	(15.82)	(9.32)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2023

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CLVR Clever Leaves Holdings Inc.	$96.5M	— (loss-making)	— (loss-making)	+5.36% (above 0%: growing)	n/m	+70.31% (above 0%: growing)	(7.46%)	(105.91%)	Compare
CTOR Citius Oncology, Inc.	$69.4M	— (loss-making)	—	—	n/m	0.00%	67.07%	(583.53%)	Compare
TLPH Talphera, Inc.	$55.5M	— (loss-making)	— (loss-making)	−99.60% (below 0%: shrinking)	n/m	−33.11% (below 0%: shrinking)	100.00%	0.00%	Compare
INCR InterCure Ltd.	$55.1M	8.8×	— (loss-making)	−6.53% (below 0%: shrinking)	n/m	+389.50% (above 0%: growing)	32.04%	0.00%
ZYBT Zhengye Biotechnology Holding Limited	$44.6M	—	—	—	—	−69.31% (below 0%: shrinking)	—	—	Compare
SCYX SCYNEXIS, Inc.	$38.9M	— (loss-making)	— (loss-making)	−8.56% (below 0%: shrinking)	n/m	−98.60% (below 0%: shrinking)	100.00%	(3,308.51%)	Compare
IXHL Incannex Healthcare Inc.	$36.1M	— (loss-making)	— (loss-making)	−92.31% (below 0%: shrinking)	n/m	+327.73% (above 0%: growing)	100.00%	0.00%	Compare
RMTI Rockwell Medical, Inc.	$32.2M	— (loss-making)	— (loss-making)	+10.63% (above 0%: growing)	n/m	−12.92% (below 0%: shrinking)	18.24%	(5.97%)	Compare
CPHI China Pharma Holdings, Inc.	$31.3M	— (loss-making)	— (loss-making)	−7.56% (below 0%: shrinking)	n/m	−113.57% (below 0%: shrinking)	8.82%	(150.99%)	Compare
Median of peers	$41.7M	—	—	−8.06%	—	−23.02%	67.07%	(105.91%)

All 86 Drug Manufacturers Specialty & Generic stocks →

InterCure Ltd. (INCR) key facts

Strength: InterCure Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $78.5 million, up 18.4% from fiscal 2024.
InterCure Ltd. (INCR) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, INCR traded at $4.66, a market capitalization of $55.1 million.
Return on equity was −9.32% and debt-to-equity 0.27.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 0.14 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.